| GIF | gastric intrinsic factor; growth hormone-inhibiting factor |
|---|---|
| HGF | hepatocyte growth factor; hyperglycemic-glucogenolytic factor |
| HLF | heat-labile factor; hepatic leukemia factor |
| LAF | laminar air flow; Latin American female; leukocyte-activating factor; lymphocyte-activating factor |
| LF | labile factor; lactoferrin; laryngofissure; Lassa fever; latex fixation; left foot; left forearm; le... |
| factor A | A component of the properdin system; a hydrazine-sensitive b1-globulin (mw about 180,000), now known to be C3 (third component of complement). (05 Mar 2000) |
|---|---|
| factor analysis, statistical | A set of statistical methods for analyzing the correlations among several variables in order to estimate the number of fundamental dimensions that underlie the observed data and to describe and measure those dimensions. It is used frequently in the development of scoring systems for rating scales and questionnaires. (12 Dec 1998) |
| factor B | <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase. Registry number: EC 3.4.21.47 (12 Dec 1998) |
| factor D | <enzyme> A serum protein which during the alternate pathway of complement activation converts the inactive properdin factor b to c3 convertase. Registry number: EC 3.4.21.46 (12 Dec 1998) |
| factor E | A serum protein (mw 160,000) required for activation of C3 (third component of complement) by cobra venom factor. See: properdin system. (05 Mar 2000) |
| factor Gm | A factor that determines certain of the allotypes of human immunoglobulins; found only on the g chains of IgG (gamma-globulin). (05 Mar 2000) |
| factor H | Former designation for biotin, vitamin B12 analogue or precursor, a glycoprotein that regulates the activity of complement factor C3b; a deficiency results in the lack of inhibition of the alternative haemolytic pathway leading to continuous activation and consumption of factor C3 (haemolytic uraemic syndrome). (05 Mar 2000) |
| factor I | <haematology> A protein which is synthesised by the liver. Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting. A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen. Synonym: fibrinogen. (15 Nov 1997) |
| factor II | <haematology> A protein which is synthesised by the liver. Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting. A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen. Synonym: thrombin. (15 Nov 1997) |
| factor IIa | <enzyme> Protease (34 kD) generated in blood clotting that acts on fibrinogen to produce fibrin. Consists of two chains, A and B, linked by a disulphide bond. B chain has sequence homology with pancreatic serine proteases: cleaves at Arg Gly. Thrombin is produced from prothrombin by the action either of the extrinsic system (tissue factor + phospholipid) or, more importantly, the intrinsic system (contact of blood with a foreign surface or connective tissue). Both extrinsic and intrinsic systems activate plasma factor X to form factor Xa which then, in conjunction with phospholipid (tissue derived or platelet factor 3) and factor V, catalyses the conversion. (18 Nov 1997) |
| factor II assay | A test used to measure the activity of a blood clotting factor (thrombin). This test may be used to evaluate excessive bleeding. Abnormally low factor II assays may be seen in the following conditions: congenital deficiency of factor II, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration. (27 Sep 1997) |
| factor II deficiency | A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs. Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases. (27 Sep 1997) |
| factor III | In the clotting of blood, tissue factor or thromboplastin; it initiates the extrinsic pathway by reacting with factor VII and calcium to form factor VIIa. See: thromboplastin. (05 Mar 2000) |
| factor Inv | A factor that determines certain of the allotypes of human immunoglobulins; found on the kappa chains of IgG, IgA, IgM, and Bence Jones protein. (05 Mar 2000) |
| factor IV | In the clotting of blood, calcium ions. (05 Mar 2000) |